OmniAb (OABI) Initiation of Coverage
Investment Summary
- OmniAb, Inc. (OABI) is a technology licensing company specializing in antibody and peptide discovery platforms, leveraging proprietary transgenic animal technologies and AI-driven screening tools.
- Over the last three years, OmniAb has grown its partner and program base significantly, with active partners rising from 77 in FY2023 to 107 in FY2025, and active programs from 325 to 407.
- Financial performance has been challenged by declining revenue and persistent net losses: revenue fell from $34.2M in FY2023 to $18.7M in FY2025, while net loss widened from -$50.6M to -$64.8M.
- The company launched new platforms (OmniUltra, xPloration) and expanded into instrument sales, diversifying its revenue streams and increasing contracted milestone potential (> $3B).
- Risks include revenue volatility, high dependence on milestone-driven income, partner concentration, and ongoing need for capital raises.
Business Overview
OmniAb licenses advanced antibody discovery technologies to pharmaceutical, biotech, and academic partners. Its platforms include transgenic animals (OmniRat, OmniMouse, OmniChicken, OmniUltra), AI-powered screening (xPloration), and specialized capabilities (OmnidAb, OmniDeep). Revenue is generated from license fees, milestones, services, royalties, and instrument sales.
Financial Snapshot: Key Material Information (Fiscal Years)
| Fiscal Year | Revenue ($M) | Net Loss ($M) | Cash & ST Investments ($M) | Active Partners | Active Programs | Clinical Programs | Approved Products | R&D Expense ($M) | G&A Expense ($M) |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | 18.7 | -64.8 | 54.0 | 107 | 407 | 27 | 3 | 47.8 | 29.2 |
| 2024 | 26.4 | -62.0 | 59.4 | 91 | 363 | 28 | 3 | 55.1 | 30.7 |
| 2023 | 34.2 | -50.6 | 87.0 | 77 | 325 | 32 | 3 | 56.5 | 33.3 |
Quarterly Financial Snapshot (Most Recent Quarters)
| Quarter | Revenue ($M) | Net Loss ($M) | Cash ($M) | Operating Expense ($M) | Active Partners | Active Programs |
|---|---|---|---|---|---|---|
| Q1 2026 | 14.4 | -7.7 | 49.1 | 22.3 | 107 | 409 |
| Q4 2025 | 8.4 | -14.2 | 54.0 | 24.1 | 107 | 407 |
| Q2 2025 | 3.9 | -15.9 | 41.6 | 20.1 | 100 | 381 |
| Q1 2025 | 4.2 | -18.2 | 43.6 | 23.0 | 95 | 378 |
Bullish and Bearish Points
| Bullish Points | Bearish Points |
|---|---|
| Large and growing addressable market for antibody therapeutics ($250B in 2023, $330B+ by 2029) | Revenue declined -29% YoY in FY2025; net losses continue |
| Expanding partner and program base (107 partners, 407 programs, 27 clinical programs) | High dependence on a few partners (top 3 = 37% of FY2025 revenue) |
| Proprietary, multi-species transgenic animal platforms and AI-powered screening technologies | Uncertainty in timing/likelihood of milestone and royalty payments; long drug development cycle |
| Three approved products and increasing royalty revenue | Significant competition from well-funded peers (AbCellera, Alloy, Regeneron, etc.) |
| Strong cash position post-PIPE ($54M at year-end) | Ongoing need for capital raises; warrants are out-of-the-money |
| New product launches (xPloration instrument, OmniUltra platform) | Impairment charges and restructuring costs in FY2025 |
Positive and Negative Catalysts
| Positive Catalysts | Negative Catalysts |
|---|---|
| New partner signings and expansion of existing partnerships | Further declines in license, milestone, or service revenue |
| Advancement of partnered programs into later-stage clinical trials or approvals | Partner program terminations or clinical failures |
| Additional product launches (e.g., xPloration, OmniUltra) | Delays or failures in new technology adoption by partners |
| Increases in royalty revenue from commercialized products | Regulatory or reimbursement headwinds impacting partner commercialization |
| Strategic M&A or technology acquisitions | Increased competition or loss of key intellectual property |
| Successful cost control and improved operating leverage | Need for further dilutive capital raises or inability to achieve profitability |
Top Questions to Ask Before Investing
- Revenue Visibility: What is the outlook for license, milestone, and service revenue over the next 1-2 years? How predictable are these revenue streams given partner dependencies?
- Royalty Ramp: When do management expect royalties to become a material portion of total revenue? What is the pipeline of late-stage partnered programs?
- Partner Concentration Risk: How is OmniAb managing its reliance on a small number of partners for a significant share of revenue?
- Competitive Differentiation: What are the key technical and commercial differentiators versus competitors like AbCellera, Alloy, and Regeneron?
- Capital Needs: Is the current cash balance sufficient to reach profitability, or will further equity raises be required?
- Product Adoption: What is the uptake and feedback from partners on new offerings such as xPloration and OmniUltra?
- Impairments and Restructuring: Are there further risks of asset impairments or restructuring charges?
- Regulatory and Market Risks: How could changes in drug pricing, reimbursement, or regulation impact the business model and partner economics?
- Warrants and Dilution: With warrants out-of-the-money, what is the plan for future capital structure and potential dilution?
- Long-Term Vision: What is management’s vision for OmniAb’s role in the evolving antibody discovery ecosystem?
